Relay Therapeutics, Inc. Common Stock (RLAY) — 分析摘要
Relay Therapeutics, Inc. Common Stock（RLAY）的市值为4.10十亿美元，最近一年的营收同比增长了+53.4%。净利润率为-1800.6%。当前市盈率为-15.0倍。
核心要点
- 营收同比变化+53.4%
- 净利润率-1800.6%
- 市盈率-15.0倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，RLAY的营收增长为+53.4%，市盈率为-15.0倍。
Relay Therapeutics, Inc. Common Stock (RLAY)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -2776.9% — 严重经营亏损
净利率为 -2554.4% — 亏损超过收入（可能含一次性费用）
营收较上一期下降 30.5%。
最新报表显示自由现金流为负。
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
192
总部
CAMBRIDGE, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。